Protocol No.: M20-259

Title
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy
Principal Investigator
Kupec, Justin
Phase
III
Age Group
Adult
Applicable Disease Site
Other
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Yanmin Li
Research Associate
Phone: +1 304-293-3634

View on ClinicalTrials.gov